ADAPTIMMUNE THERAPEUTICS PLC
(ADAPY)Financial Statements · SEC EDGAR XBRL
Revenue
$178.0M
+195.3%
Net Income
-$70.8M
+37.8%
EPS
$-0.05
+44.4%
Gross Margin
100.0%
Op. Income
-$68.8M
+50.8%
FCF
-$74.1M
+49.1%
Source: SEC EDGAR XBRL
Breakdown
Revenues
Revenues
Total Revenues
Cost of Revenues
Gross Profit
Operating Expenses & Income
Selling General & Admin
Research & Development
Operating Income
Non-Operating Income/Expense
Other Non-Operating Income
Pre-Tax Income
Income Tax Expense
Net Income
EPS (Basic)
EPS (Diluted)
Shares Outstanding (Diluted)